Biolase receives CE mark approval for all-tissue laser

Feb. 4, 2011
IRVINE, CA — (Marketwire – Feb.3, 2011) — BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser manufacturer and distributor, today announced that it has received Conformite Europeene (CE) Mark approval for the Waterlase® iPlus™ System dual-wavelength all-tissue laser. Receipt of the CE Mark enables BIOLASE to initiate commercial sales of the system throughout the European Union.

IRVINE, CA — (Marketwire – Feb. 3, 2011) — BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser manufacturer and distributor, today announced that it has received Conformite Europeene (CE) Mark approval for the Waterlase® iPlus™ System dual-wavelength all-tissue laser. The Waterlase iPlus, BIOLASE's new flagship laser product, is the most advanced laser in the market and the first major breakthrough in all-tissue laser technology since the Waterlase MD™ was introduced in 2005. Receipt of the CE Mark enables BIOLASE to initiate commercial sales of the system throughout the European Union.

Click here to read more.